auranofin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4122 34031-32-8

Description:

MoleculeDescription

Synonyms:

  • auranofin
  • ridaura
An oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. Its exact mechanism of action is unknown, but it is believed to act via immunological mechanisms and alteration of lysosomal enzyme activity. Its efficacy is slightly less than that of injected gold salts, but it is better tolerated, and side effects which occur are potentially less serious.
  • Molecular weight: 678.48
  • Formula: C20H34AuO9PS
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
6 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 60 % Benet LZ, Broccatelli F, Oprea TI

Approvals:

DateAgencyCompanyOrphan
May 24, 1985 FDA PROMETHEUS LABS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M01CB03 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
SPECIFIC ANTIRHEUMATIC AGENTS
Gold preparations
CHEBI has role CHEBI:35705 immunosuppressive agents
CHEBI has role CHEBI:35842 anti-rheumatic drugs
CHEBI has role CHEBI:64670 thioredoxin reductase (NADPH) inhibitors
MeSH PA D018501 Antirheumatic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148
Psoriasis with arthropathy off-label use 33339001
Felty's syndrome off-label use 57160007 DOID:11042
Juvenile rheumatoid arthritis off-label use 410795001
Necrotizing enterocolitis in fetus OR newborn contraindication 2707005
Hypertensive disorder contraindication 38341003 DOID:10763
Eczema contraindication 43116000
Chronic heart failure contraindication 48447003
Fibrosis of lung contraindication 51615001 DOID:3770
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Colitis contraindication 64226004 DOID:0060180
Diabetes mellitus contraindication 73211009 DOID:9351
Sjögren's syndrome contraindication 83901003 DOID:12894
Leukopenia contraindication 84828003 DOID:615
Kidney disease contraindication 90708001 DOID:557
Urticaria contraindication 126485001
Inflammatory disease of liver contraindication 128241005
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Disease of liver contraindication 235856003 DOID:409
Eruption of skin contraindication 271807003 DOID:0050486
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Ultraviolet light therapy contraindication 363695005
Erythroderma contraindication 399992009
Severe Debilitation contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Arachidonate 5-lipoxygenase Enzyme WOMBAT-PK
Alpha-2A adrenergic receptor GPCR Ki 6.48 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.44 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.65 DRUG MATRIX
Glucocorticoid receptor Nuclear hormone receptor Ki 6.22 DRUG MATRIX
Adenosine receptor A3 GPCR Ki 6.02 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 6.41 DRUG MATRIX
Thioredoxin reductase 1, cytoplasmic Enzyme WOMBAT-PK
Tyrosine-protein kinase Fyn Kinase IC50 5.92 DRUG MATRIX
Transient receptor potential cation channel subfamily A member 1 Ion channel ACTIVATOR EC50 6 IUPHAR

External reference:

IDSource
4018014 VUID
N0000146358 NUI
D00237 KEGG_DRUG
4018014 VANDF
C0004320 UMLSCUI
CHEBI:2922 CHEBI
CHEMBL1366 ChEMBL_ID
D001310 MESH_DESCRIPTOR_UI
DB00995 DRUGBANK_ID
6306 IUPHAR_LIGAND_ID
3972 INN_ID
3H04W2810V UNII
70788951 PUBCHEM_CID
1227 RXNORM
1189 MMSL
4231 MMSL
d00818 MMSL
002398 NDDF
18002004 SNOMEDCT_US
387100001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
RIDAURA HUMAN PRESCRIPTION DRUG LABEL 1 54766-093 CAPSULE 3 mg ORAL NDA 23 sections
RIDAURA HUMAN PRESCRIPTION DRUG LABEL 1 65483-093 CAPSULE 3 mg ORAL NDA 23 sections